Surprisingly, a recent case report demonstrated that a patient with metastatic intrahepatic cholangiocarcinoma carrying a BRCA1-associated protein 1 (BAP1) mutation and RAD21 amplification benefited from PARP inhibitor treatment (36). This evidence concerns the gene RAD21 and intrahepatic cholangiocarcinoma.